Expanding role of positron emission tomography in cancer of the uterine cervix

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 5, 2006, Pages 463-469

  Rajendran, Joseph G ^a,b,c   Greer, Benjamin E ^a,b  

^a University of Washington ^*

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer cervix; FDG; Molecular imaging; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; COPPER 64; TRACER;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; UNITED STATES; UTERINE CERVIX CANCER;

EID: 33747601100     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0038     Document Type: Article

References (73)

1. Vergote I, Amant F, Berteloot P, Van Gramberen M. Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer. Int J Gynecol Cancer 2002;12:22-26.
2. Goff BA, Muntz HG, Paley PJ, et al. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999;74:436-442.
3. Buchsbaum HJ. Extrapelvic lymph node metastases in cervical carcinoma. Am J Obstet Gynecol 1979;133:814-824.
4. Singh AK, Grigsby PW, Dehdashti F, et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003;56:489-493.
5. Grigsby PW, Dehdashti F, Siegel BA. FDG-PET evaluation of carcinoma of the cervix. Clin Positron Imaging 1999;2:105-109.
6. Belhocine T, Thille A, Fridman V, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002;87:90-97.
7. Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546-551.
8. Tran BN, Grigsby PW, Dehdashti F, et al. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003;90:572-576.
9. Belhocine T, Kridelka F, Thille A, et al. Staging of primary cervical cancers: the role of nuclear medicine. Grit Rev Oncol Hematol 2003;46:275-284.
10. Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003;98:2028-2038.
11. Unger JB, Ivy JJ, Ramaswamy MR, et al. Whole-body [18F]flouro-2- deoxyglucose positron emission tomography scan staging prior to planned radical hysterectomy and pelvic lymphadenectomy. Int J Gynecol Cancer 2005;15:1060-1064.
12. Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249-257.
13. Husseinzadeh N, Shrake P, DeEulis T, et al. Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study. Gynecol Oncol 1994;52:326-331.
14. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001;218:776-782.
15. Narayan K, Hicks RJ, Jobling T, et al. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001;11:263-271.
16. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19:3745-3749.
17. Sironi S, Buda A, Picchio M, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 2006;238:272-279.
18. Lin WC, Hung YC, Yeh LS, et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003;89:73-76.
19. Tsai CS, Chang TC, Lai CH, et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MR1/CT. Int J Radiat Oncol Biol Phys 2004;58:1506-1512.
20. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d- glucose positron emission tomography in cervical cancer. J Clin Oncol 2003;21:3651-3658.
21. Reinhardt MJ, Technau-Ihling K, Altehoefer C, et al. Lymphangiography causes false-positive findings on 18F-FDG PET imaging. Anticancer Res 2003;23:2941-2944.
22. Wootipoom V, Lekhyananda N, Phungrassami T, et al. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 2004;94:636-642.
23. Wilailak S, Rochanawutanon M, Srisupundit S, et al. Flow cytometric analysis of DNA ploidy and S-phase fraction of Stage IIIB cervical carcinoma. Eur J Gynaecol Oncol 2004;25:428-430.
24. Kang JO, Hong SE. The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. J Korean Med Sci 2004;19:693-697.
25. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
26. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154.
27. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
28. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-432.
29. Hawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002;94:3277-3284.
30. Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003;44:192-197.
31. Racker E, Spector M. Warburg effect revisited: merger of biochemistry and molecular biology. Science 1981;213:303-307.
32. Koyama K, Okamura T, Kawabe J, et al. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 2003;44:353-358.
33. Adam LE, Karp JS, Daube-Witherspoon ME, Smith RJ. Performance of a whole-body PET scanner using curve-plate NaI(T1) detectors. J Nucl Med 2001;42:1821-1830.
34. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-1063.
35. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844.
36. Bristow RE, Giuntoli RL 2nd, Pannu HK, et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99:294-300.
37. Kim SK, Kang KW, Roh JW, et al. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging 2005;32:757-763.
38. Grigsby PW. Cervical cancer: combined modality therapy. Cancer J 2001;7[suppl 1]:S47-S50.
39. Sasaoka M, Fuwa N, Asano A, et al. Patterns of failure in carcinoma of the uterine cervix treated with definitive radiotherapy alone. Am J Clin Oncol 2001;24:586-590.
40. Scarfone C, Lavely WC, Cmelak AJ, et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 2004;45:543-552.
41. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-1182.
42. Grigsby PW, Perez CA, Chao KS, et al. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2001;49:733-738.
43. Rajendran JG, Schwartz DL, Kinahan PE, et al. Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer. J Nucl Med 2003;44:415, 127P.
44. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667-1673.
45. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and paraaortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-266.
46. Malyapa RS, Mutic S, Low DA, et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys 2002;54:1140-1146.
47. Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2004;58:1289-1297.
48. Ahmed RS, Kim RY, Duan J, et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004;60:505-512.
49. Halfpenny W, Hain SF, Biassoni L, et al. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002;86:512-516.
50. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-135.
51. Allal AS, Taussky D, Mach N, et al. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys 2004;58:1431-1436.
52. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas tteated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398-1404.
53. Sakamoto H, Nakai Y, Ohashi Y, et al. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Acta Otolaryngol Suppl 1998;538:254-260.
54. Yen TC, See LC, Chang TC, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45:1632-1639.
55. Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167-2171.
56. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942-946.
57. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-658.
58. Hustinx R, Eck SL, Alavi A. Potential Applications of PET Imaging in Developing Novel Cancer Therapies. J Nucl Med 1999;40:995-1002.
59. Sun SS, Chen TC, Yen RF, et al. Value of whole body 18F-fluoro- 2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001;21:2957-2961.
60. Havrilesky LJ, Wong TZ, Secord AA, et al. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003;90:186-190.
61. Ryu SY, Kim MH, Choi SC, et al. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:347-352.
62. Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991;51:6098-6102.
63. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
64. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8[suppl]:S62-S67.
65. Hockel M, Schlenger K, Mitze M, et al. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996;6:3-9.
66. Okunieff P, de Bie J, Dunphy EP, et al. Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. Br J Cancer 1996;27:185-190.
67. Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1 alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:494-501.
68. Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003;44:1051-1056.
69. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266-271.
70. Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol 2004;6:55-62.
71. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998;18:805-823; discussion 823-804.
72. Amit A, Beck D, Lowenstein L, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006;100:65-69.
73. Sakurai H, Suzuki Y, Nonaka T, et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy-tumor volume and FDG uptake value. Gynecol Oncol 2006;100:601-607.